Therapeutic applications of the nonpeptide partial agonists such as FR190997: have been proposed: topically, as agents that decrease excessive intraocular pressure via B2R stimulation in intraoccular structures following efficient tissue penetration [77] and in oncology, where B2R downregulation following persistent endocytosis may be salutary in tumor cells where overexpressed kinin receptors fuel proliferation [78]. Here, BDKRB2 is linked to neoplasm.